NCI Requests Feedback on Genomic Data Submission Form
Published Date: 4/1/2026
Notice
Summary
The National Cancer Institute (NCI) wants your thoughts on a form used to submit cancer genetic data to their Genomic Data Commons. If you work with cancer research data, this is your chance to comment before May 1, 2026. There’s no cost to you, but your feedback helps keep data collection smooth and useful for science!
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09808 — Government Owned Inventions Available for License: Synergistic Interactions for Improved Cancer Treatment
The National Cancer Institute is offering a cool new cancer treatment invention called hetIL-15 that works better when combined with other drugs like Fenofibrate and quizartinib. This combo could help patients by making immune cells stronger and safer, potentially beating tough cancers like breast and pancreatic tumors. Researchers and companies interested in developing or licensing this tech should act soon to join the fight against cancer and bring these treatments to life.
2026-09292 — Government Owned Inventions Available for License: Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1
The government has a cool new discovery that makes certain immune cells, called T cells, better at fighting cancer by turning off some ‘brakes’ inside them. This could lead to stronger treatments for cancer, infections, and autoimmune diseases. Companies interested in developing this technology can license it now, potentially speeding up new, powerful therapies and boosting health outcomes.
2026-08606 — Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding several closed virtual meetings in June 2026 to review and evaluate grant applications related to aging, genetics, neurodegeneration, and pediatric critical care. These meetings protect sensitive info like trade secrets and personal data, so they’re not open to the public. Researchers applying for grants should note these dates as they impact funding decisions and the review process timeline.
2026-08638 — Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding several closed virtual meetings in June 2026 to review and decide on grant applications. These meetings affect researchers seeking funding for brain, behavior, and imaging studies, keeping sensitive info private. No new costs or deadlines are announced, but these reviews shape which projects get money next.
2026-08456 — Proposed Collection; 60-Day Comment Request; NIH Office of Intramural Training & Education-Application, Registration, and Alumni Systems Office of the Director
The NIH Office of Intramural Training & Education wants your thoughts on updating their application, registration, and alumni systems. This affects students, trainees, and alumni who use these systems, aiming to make things smoother and less time-consuming. You’ve got 60 days to share your ideas before they finalize the changes—no extra costs involved, just better tech and less hassle!
2026-08461 — Submission for OMB Review; 30-Day Comment Request Application and Impact of Clinical Research Training on Healthcare Professionals in Academia and Clinical Research (Office of the Director)
The NIH is asking for public feedback on a survey about how clinical research training helps healthcare pros in schools and labs. This is a quick 30-day chance to share your thoughts before June 1, 2026. No big costs or changes yet—just making sure the survey is clear and useful for everyone involved.
Previous / Next Documents
Previous: 2026-06316 — Issuance of Priority Review Voucher; Rare Pediatric Disease Product; YUVIWEL (navepegritide)
The FDA just gave Ascendis Pharma a special priority review voucher for their new rare pediatric disease drug, YUVIWEL, which helps kids with achondroplasia grow taller. This voucher speeds up future drug reviews and can be a valuable asset, saving time and potentially money. Approved on February 27, 2026, this move highlights the FDA’s commitment to fast-tracking treatments for rare childhood conditions.
Next: 2026-06319 — Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; Pacific Islands Logbook Family of Forms
NOAA is asking to keep collecting fishing reports from Pacific Islands vessel operators to track fish stocks and protect endangered sea creatures. About 576 fishers spend around 16 minutes each reporting their trips and catches. This extension keeps the rules steady with no new costs, and you’ve got 30 more days to share your thoughts!